ClinicalTrials.gg
RecruitingNCT07334483Updated Jan 12, 2026

A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC

A Phase 2 interventional study of Yttrium [90Y] Microsphere Injection and Conventional transcatheter arterial chemoembolization in HCC, sponsored by GrandPharma (China) Co., Ltd.. Recruiting at 3 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by GrandPharma (China) Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is A Randomized, Active-Controlled, Open-Label National Multicenter Phase 2 Registration Clinical Study of Yttrium [90Y] Microsphere Injection in Combination with Camrelizumab and/or Apatinib and Yttrium [90Y] Microsphere Injection Alone versus Conventional Transcatheter Arterial Chemoembolization (cTACE) in the Treatment of Unresectable or Non-Ablative, Non-Metastatic Hepatocellular Carcinoma (HCC). Its aim is to evaluate the efficacy and safety of yttrium [90Y] resin microsphere injection combined with Camrelizumab and/or apatinib compared with yttrium [90Y] resin microsphere injection alone in the treatment of inoperable or ablatable, non-metastatic HCC.

Read the detailed description

This is a prospective, randomized, active-controlled, open-label, multicenter Phase 2 clinical study to evaluate the efficacy and safety of yttrium [90Y] microsphere injection in combination with camrelizumab and/or apatinib and yttrium [90Y] microsphere injection alone versus cTACE in the treatment of unresectable or non-ablative, non-metastatic HCC.

A total of at least 120 subjects with unresectable or non-ablative, non-metastatic HCC are planned to be enrolled and randomly assigned to groups A, B, C and D in a 1:1:1:1 ratio, that is, yttrium [90Y] microsphere injection + camrelizumab + apatinib group (A), yttrium [90Y] microsphere injection + camrelizumab group (B), yttrium [90Y] microsphere injection group (C) and cTACE group (D). The above treatment will continue until the criteria for withdrawal from study treatment are met, whichever occurs first. Subjects will receive yttrium [90Y] microsphere injection alone or in combination with camrelizumab and/or apatinib for up to 18 months.

The primary endpoint of the Phase 2 study is ORR assessed by BICR based on mRECIST criteria. The key secondary endpoint is PFS assessed by BICR based on mRECIST criteria.

02

Conditions studied

  • HCC

Keywords

  • Yttrium [90Y] Microsphere Injection
03

In context

Lead sponsor

GrandPharma (China) Co., Ltd. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who voluntarily participate in this study, sign the form (ICF), and are able to comply with the diagnosis, treatment, observation, follow-up visit and related procedures specified in this protocol, with good compliance.
  2. Patients aged ≥ 18 and ≤ 75, regardless of gender.
  3. HCC confirmed by pathological histology/cytology, or meeting the clinical diagnostic criteria in the Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2024 Edition) established by the National Health Commission.
  4. Patients who are not suitable for surgery (including hepatectomy and liver transplantation) or ablation treatment based on the judgment of investigator or clinical practice guidelines, or refuse surgery or ablation treatment.
  5. China Liver Cancer Clinical Staging (CNLC): Ib-IIIa. Vp4 portal vein tumor thrombus invasion will be excluded, if combined with Vp1-3 portal vein tumor thrombus, the tumor thrombus must be located on the same side of the liver lobe as the targeted tumor area.
  6. Patients with at least 1 according to v1.1 and criteria.
  7. Patients who have been evaluated by Yttrium [90Y] Microsphere Injection Selective Internal Radiation Therapy and Dose Evaluation Committee as suitable for SIRT treatment.
  8. For yttrium [90Y] microsphere injection, camrelizumab and apatinib, there are no for use in the product instructions and clinical practice guidelines. Patients who are suitable for cTACE treatment, have no contraindications to use in clinical practice guidelines, are expected to be able to use up to 4 cTACE treatments for localized liver lesions within 24 weeks during the study period, and are expected to receive 1-2 cTACE treatments for a single lesion.
  9. PS score: 0-1.
  10. liver function classification: Class A or Class B with ≤7 points.
  11. ≥3 months.
  12. If the subject has or infection, the following criteria must be met:

    i. Subjects with HBV infection (HBsAg and/or HBV-DNA positive): Subjects should receive antiviral treatment with one of the 4 drugs recommended by the national clinical guidelines for hepatitis B (tenofovir disoproxil fumarate, tenofovir alafenamide fumarate, tenofovir amibufenamide and entecavir) for at least 7 days before the first study treatment to achieve HBV-DNA \< 2000 IU/mL or \< 104 copies/mL. The standardized antiviral treatment must be received throughout the study.

    ii. If HCV-Ab is positive, the blood HCV RNA must be negative.

  13. Patients who have basically normal organ and bone marrow functions:

    i. Hematology (corrective treatment such as any blood components or cell growth factors is not allowed within 7 days before the laboratory tests): (ANC) ≥ 1.5 × 109/L; count (PLT) ≥ 75 × 109/L; (HGB) ≥ 90 g/L.

    ii. Liver function (human albumin or plasma transfusion is not allowed within 7 days before the laboratory tests): Serum total (TBIL) ≤ 2 × (ULN); (ALT) and aspartate aminotransferase (AST) ≤ 5 × ULN, alkaline phosphatase (ALP) ≤ 5 × ULN; serum albumin ≥ 30 g/L.

    iii. Renal function: Serum creatinine (Cr) ≤ 1.5 × ULN, or the calculated value of (CrCI, estimated according to Cockcroft-Gault formula) ≥ 50 mL/min. Urinalysis results show that urine protein is \< 2+ (if urine protein is ≥ 2+, the 24-hour urine protein quantitative test should be performed, and patients can be enrolled if the 24-hour urine protein quantification is \< 1.0 g).

    iv. Coagulation function: (INR) ≤ 1.8, or prothrombin time (PT) exceeds the range of normal control ≤ 4 seconds.

  14. Patients of should use effective measures from the signing of the ICF to at least 3 months after the last study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Cholangiocarcinoma, combined hepatocellular-cholangiocarcinoma, sarcomatoid hepatocellular carcinoma and fibrolamellar hepatocellular carcinoma confirmed by pathological histology or cytology.
  2. Invasive HCC, that is, imaging shows that microscopic or small tumor nodules are diffusely distributed in a certain liver lobe or the entire liver.
  3. Based on liver volume, the tumor burden is relatively large (>50%).
  4. Presence of hepatic vein or inferior vena cava tumor thrombus, or involvement of the superior mesenteric vein or more distant end.
  5. Patients with other malignant tumors other than HCC within 5 years or at the same time. However, patients with cured localized tumors such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, prostate cancer in situ, cervical cancer in situ and breast cancer in situ can be enrolled.
  6. Conversion therapies such as interventional and targeted immunotherapy have been used before hepatectomy, including conversion of functional residual liver volume (using ALPPS or PVE) and oncology conversion therapy.
  7. Previous systemic anti-tumor treatment for HCC, including molecular targeted drugs, systemic chemotherapy and immunotherapy (, antibody-drug conjugate [ADC], immune cells, oncolytic viruses and tumor vaccines, etc.).
  8. Use of Chinese patent medicines and modern Chinese medicine preparations with anti-liver cancer indications within 7 days before randomization.
  9. Previous local treatment for liver lesions, including TACE, transarterial embolization (TAE), hepatic artery infusion chemotherapy (HAIC), radiotherapy, or ablation of target liver lesions, injection of oncolytic viruses, and internal/external radiation therapy. In the case of therapy after radical resection, patients who have only received one TACE can be enrolled.
  10. Previous solid organ (such as liver transplantation) or stem cell transplantation (except for patients who have only received corneal transplantation).
  11. Patients with bile duct obstruction due to any reason that has not been resolved before randomization.
  12. Patients with decompensated cirrhosis and severe liver function impairment ( Grade C) before randomization, including severe jaundice, hepatic encephalopathy, hepatorenal syndrome or ascites (i.e. clinically symptomatic moderate or severe ascites requiring therapeutic puncture, drainage or Child-Pugh ascites score > 2).
  13. Patients with clinically symptomatic pleural effusion and pericardial effusion requiring puncture and drainage before randomization. However, patients who have received puncture and drainage within 2 weeks before enrollment and only show a small amount of effusion on imaging without clinical symptoms can be enrolled.
  14. History of iodine contrast agent allergy of grade II or above, or inability to undergo enhanced liver CT scan due to any reason.
  15. Patients who are unable to swallow the drug, have malabsorption syndrome, incomplete gastrointestinal obstruction or any condition that significantly affects the gastrointestinal absorption of apatinib mesylate before randomization.
  16. History of active pulmonary tuberculosis. For subjects suspected of having active pulmonary tuberculosis, the definitive diagnosis should be made in combination with chest imaging, sputum, clinical symptoms and signs.
  17. Patients with congenital or acquired immune deficiency (such as infection), active syphilis, or co-infection of and C.
  18. Patients with cardiovascular and cerebrovascular diseases before randomization:

    i. Uncontrollable hypertension (systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg) after optimal antihypertensive treatment, with a previous history of hypertensive crisis or hypertensive encephalopathy.

    ii. History of myocardial infarction, unstable angina pectoris, cerebral infarction, cerebral haemorrhage or any other major cardiovascular and cerebrovascular accident within 6 months before randomization.

    iii. Congestive heart failure classified as grade 2 or above by the (NYHA): (LVEF) \< 50%.

    iv. Severe cardiac rhythm or conduction abnormalities, including supraventricular or ventricular arrhythmias requiring treatment, value ≥ 450 ms (males)/≥ 470 ms (females), or second-degree or third-degree atrioventricular block.

    v. History of myocarditis or related examinations suggest active myocarditis. vi. Subjects with heart disease who are assessed by the investigator to be intolerant of other tests.

  19. Patients with a history of interstitial pneumonia or interstitial lung disease, or a previous history of interstitial pneumonia or interstitial lung disease requiring therapy, or other pulmonary fibrosis and organising pneumonia that may interfere with the judgment and treatment of immune/SIRT-related pulmonary toxicity.
  20. Patients with severe hemorrhagic tendency or coagulation dysfunction, or receiving thrombolytic therapy; patients who have received or are receiving conventional doses of nonsteroidal anti-inflammatory drugs (such as aspirin, indomethacin ibuprofen and naproxen), antiplatelet drugs (such as clopidogrel, ticlopidine, dipyridamole and cilostazol) or anticoagulants (such as warfarin and low molecular weight heparin) within 10 days before randomization.
  21. Subjects who have participated in other clinical studies and used the drug or device within 30 days before randomization.
  22. Patients with active diseases requiring systemic treatment (such as the use of disease-modifying drugs, corticosteroids or agents) within 1 year before randomization or a history of autoimmune diseases that may recur. Patients receiving replacement therapy (such as thyroid hormone replacement therapy for hypothyroidism, type 1 diabetes mellitus requiring only insulin replacement therapy, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency) can be enrolled.
  23. Subjects at risk of bleeding, as follows:

    i. Subjects with history of gastrointestinal bleeding or a significant tendency to gastrointestinal bleeding within 6 months before randomization, such as esophageal or gastric variceal bleeding caused by portal hypertension, local active peptic ulcer or persistent faecal occult blood positive.

    ii. Any life-threatening bleeding event within 3 months before randomization, including the events requiring blood transfusion, surgery or local treatment, and continuous drug therapy.

    iii. Subjects with esophageal or gastric varices requiring interventional treatment within 28 days before randomization.

    iv. Untreated or incompletely treated esophageal or gastric fundus varices that are at high risk of bleeding as judged by the investigator.

  24. Abdominal fistula, gastrointestinal perforation or abdominal abscess within 6 months before randomization.
  25. Patients with intestinal obstruction and/or clinical signs or symptoms of gastrointestinal obstruction within 6 months before randomization, including incomplete obstruction related to pre-existing diseases or requiring routine parenteral hydration, parenteral nutrition or tube feeding.
  26. History of deep vein thrombosis, pulmonary embolism or any other serious thromboembolism within 3 months before randomization (except for implantable venous access port or catheter-related thrombosis, or superficial vein thrombosis).
  27. Patients who have undergone major surgery or serious trauma within 28 days before randomization (and cannot participate in the study as judged by the investigator); patients with severe unhealed wound, active ulcer or untreated fracture before randomization.
  28. Patients who have received or treatment within 28 days before randomization.
  29. Use of strong inducers or strong CYP3A4 inhibitors within 7 days before randomization.
  30. Use of immunosuppressive agents or systemic corticosteroids therapy for immunosuppression within 14 days before randomization, excluding topical corticosteroids or systemic application of low-dose prednisone (not more than 10 mg/day) or equivalent doses of other corticosteroids.
  31. Patients who have received drugs with immunomodulatory effects within 14 days before randomization, including systemic use of thymosin-α1, interferon and interleukin-II.
  32. Pregnant or lactating women, or women who need to continue breastfeeding during the study.
  33. Any other serious diseases, metabolic disorders or laboratory test abnormalities that are not suitable for treatment with the investigational drug, will affect the interpretation of the study results, or put the patient at high risk as judged by the investigator.
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Group A

    Yttrium \[90Y\] microsphere injection selective internal radiation therapy (SIRT) + camrelizumab + apatinib

    Drug: Yttrium [90Y] Microsphere Injection · Drug: Camrelizumab · Drug: Apatinib

  • Experimental
    Group B

    Yttrium \[90Y\] microsphere injection SIRT + camrelizumab

    Drug: Yttrium [90Y] Microsphere Injection · Drug: Camrelizumab

  • Experimental
    Group C

    Yttrium \[90Y\] microsphere injection SIRT

    Drug: Yttrium [90Y] Microsphere Injection

  • Active comparator
    Group D

    Conventional transcatheter arterial chemoembolization

    Other: Conventional transcatheter arterial chemoembolization

Interventions

  • DrugYttrium [90Y] Microsphere Injection

    Yttrium \[90Y\] microsphere injection should be implanted through the hepatic artery based on 99mTc-MAA SPECT/CT simulated surgery (Mapping) to evaluate the distribution of microsphere in the body, and calculate the activity required for treatment

    Also known as: Yttrium-90 resin microsphere

  • OtherConventional transcatheter arterial chemoembolization

    For the operation method of cTACE, please refer to the Clinical Practice Guidelines for Transcatheter Arterial Chemoembolization (TACE) Treatment of Hepatocellular Carcinoma in China (2023 Edition) and its related standard operating procedures (SOPs).

    Also known as: cTACE

  • The first dose of Cycle 1 should be completed within 3 days after randomization. After Cycle 1 Day 1 (C1D1), it should be dosed every 3 weeks ± 3 days. Dosing may be delayed due to holidays, but should not exceed 7 days

    Also known as: CAM

  • Apatinib will be used from Cycle 2 Day 1 (C2D1). Apatinib should be discontinued for at least 7 days before and after treatment with yttrium \[90Y\] microsphere injection

    Also known as: RIVO

06

What researchers measure

Primary outcomes

  1. ORR

    Objective Response Rate, assessed by blinded independent central review (BICR) based on mRECIST criteria

    Time frame: up to 18 months

Secondary outcomes

  1. PFS

    Progression-free survival (PFS, assessed by BICR based on mRECIST and RECIST v1.1 criteria)

    Time frame: up to 18 months

  2. ORR

    Objective Response Rate (assessed by BICR based on RECIST v1.1 criteria)

    Time frame: up to 18 months

  3. hPFS

    Hepatic Progression-free survival (hPFS) (assessed by BICR and investigator based on mRECIST criteria)

    Time frame: up to 18 months

  4. hORR

    Hepatic Objective Response Rate (hORR) (assessed by BICR and investigator based on mRECIST criteria)

    Time frame: up to 18 months

  5. PFS rate

    Progression-free survival rate at month 9(assessed by BICR based on mRECIST and RECIST v1.1 criteria respectively)

    Time frame: up to 9 months

  6. DoR

    duration of response (DoR)at month 9 (assessed by BICR based on mRECIST and RECIST v1.1 criteria respectively)

    Time frame: up to 9 months

  7. DCR

    Disease control rate (DCR)at month 9 (assessed by BICR based on mRECIST and RECIST v1.1 criteria respectively)

    Time frame: up to 9 months

  8. TTP

    Time to progress (TTP) at month 9 (assessed by BICR based on mRECIST and RECIST v1.1 criteria respectively)

    Time frame: up to 9 months

  9. TTR

    Time to tumor response (TTR)at month 9 (assessed by BICR based on mRECIST and RECIST v1.1 criteria respectively)

    Time frame: up to 9 months

  10. OS rate

    Overall survival (OS) rates at months 12/18/24

    Time frame: 12/18/24 months after the first treatment

  11. OS

    Overall survival

    Time frame: up to 18 months

07

Study locations

2 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Dec 2027, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2025
First posted
Jan 12, 2026
StartActual
Aug 22, 2025
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07334483
Lead sponsor
GrandPharma (China) Co., Ltd.
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Aug 22, 2025
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Jan 12, 2026

Study contacts

xixi hu
Contact
huxx@grandpharma.cn
027-84399665
Zhiping Yan, MD
principal investigator · Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Camrelizumab · Apatinib

Start the discussion